Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …

Immunotherapy, particularly agents targeting the immunoregulatory PD-1/PD-L1 axis,
harnesses the power of the immune system to treat cancer, with unique potential for a …

CD8+ tumor-infiltrating lymphocytes with a tissue-resident memory T (T RM) cell phenotype
are associated with favorable prognosis in patients with triple-negative breast cancer …

Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is
characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant …

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast
cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early …

PURPOSE The Standardized Definitions for Efficacy End Points (STEEP) criteria,
established in 2007 and updated in 2021 (STEEP 2.0), provide standardized definitions of …

New therapy options have changed the treatment landscape of early-stage triple-negative
breast cancer (TNBC) in recent years. Most patients are candidates for neoadjuvant …

Opinion statement Recently, the addition of PD-1 pathway targeting immune checkpoint
inhibitors (ICI) to standard neoadjuvant chemotherapy for early-stage triple-negative breast …

Background Neoadjuvant immunotherapy (nIO) has emerged as a treatment option for stage
II–III triple-negative breast cancer (TNBC). While randomised clinical trials (RCTs) …